Komipharm International Co., Ltd. announced that it expects to receive KRW 10 billion in funding from W Asset Management Co., Ltd., Susung Asset Management Co., Ltd., Focus Asset Management Co., Ltd., DB Financial Investment Co.,Ltd., Investment Arm
May 31, 2018
Share
Komipharm International Co., Ltd. (KOSDAQ:A041960) announced a private placement of 12th series unregistered coupon unguaranteed private convertible bonds for gross proceeds of KRW 10,000,000,000 on May 31, 2018. The transaction will include participation from Investment dealer of Fund 1; a fund managed by Focus Asset Management Co., Ltd. for KRW 4,000,000,000, Investment dealer of Fund 2, Investment dealer of Fund 3, Investment dealer of Fund 4; funds managed by Susung Asset Management Co., Ltd. for KRW 500,000,000, KRW 1,000,000,000 and KRW 2,500,000,000 respectively, Investment dealer of Fund 5 and Trust dealer of Fund 5; funds managed by W Asset Management Co., Ltd. for KRW 500,000,000 each, and DB Financial Investment Co.,Ltd., Investment Arm for KRW 1,000,000,000. The bonds carry no coupon rate and will mature on June 4, 2021. The bonds will be fully convertible into 326,509 shares at a fixed conversion price of KRW 30,627 per share between June 4, 2019 and May 4, 2021. The transaction is expected to close on June 4, 2018. The transaction has been approved by the board of directors of the company.
Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Companyâs main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
Komipharm International Co., Ltd. announced that it expects to receive KRW 10 billion in funding from W Asset Management Co., Ltd., Susung Asset Management Co., Ltd., Focus Asset Management Co., Ltd., DB Financial Investment Co.,Ltd., Investment Arm
KOMIPHARM INTERNATIONAL CO., LTD. 
